fbpx Skip to content

Lindus Health lands £14m Series A for clinical trial software

Lindus Health Series A
Image credit: Lindus Health

Clinical trials software startup Lindus Health has landed $18m (£14.1m) in Series A funding that was led by venture capital firm Creandum.

Other investors in the round include billionaire investor Peter Thiel, who co-founded PayPal. He was first revealed as a backer in the round in June.

Established in 2021, Lindus Health’s platform has so far been used in the UK, US and Europe for more than 80 trials and 20,000 patients. Lindus is aiming to streamline what it views as a fragmented clinical trial process.

Co-founder of the trial platform Michael Young says it can “deliver clinical trials three times faster than the industry standard”.

With the raise, the health tech startup plans to add different types of trials such as menopause, tinnitus and insomnia.

Headquartered in London, Lindus also plans to expand its headcount from 40.

“The antiquated clinical trials industry is holding back healthcare,” says Meri Beckwith, co-founder of Lindus Health. “Everyone suffers from the status quo, especially patients, who must wait decades and pay higher prices for new treatments.”

Creandum general partner Fredrik Cassel, said: “With a tech-first, AI-powered, end-to-end offering, Lindus Health is building unparalleled efficiency and quality into what has always been a manual process.”

Fredrik will join the startup’s board as part of the investment.

Lindus Health’s Series A also attracted investment from Firstminute, Seedcamp, Hambro Perks, while Amino Collective issued further money to the startup.